Form 4: Protalix BioTherapeutics Executive Granted Stock Options
SEC Form 4 Filing
Yaron Naos, Sr. VP of Operations at Protalix BioTherapeutics, acquired stock options for 100,000 shares at an exercise price of $1.10, vesting quarterly over three years.
Summary
- Yaron Naos, Sr. VP of Operations at Protalix BioTherapeutics, Inc., was granted stock options.
- The transaction occurred on September 23, 2024.
- Naos acquired options to purchase 100,000 shares of common stock at an exercise price of $1.10 per share.
- The options vest in 12 equal quarterly installments commencing on the grant date.
- The stock options expire on September 23, 2034.
- Naos also holds other options to purchase shares at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It is neither particularly positive nor negative, reflecting standard business practice.
Positives
- The granting of stock options to a senior executive aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies like Protalix.
- The size of the grant and the vesting schedule are typical for senior management roles.
- Comparing the exercise price and vesting terms to similar companies would require a more detailed analysis of executive compensation data.
Stakeholder Impact
- The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 09/23/2024 | Date of the stock option grant and transaction. |
| 03/23/2025 | Expiration date of existing options to purchase 5,000 shares at $17.20. |
| 09/13/2028 | Expiration date of existing options to purchase 60,000 shares at $5.60. |
| 08/11/2030 | Expiration date of existing options to purchase 122,656 shares at $3.59. |
| 09/07/2032 | Expiration date of existing options to purchase 340,000 shares at $1.03. |
| 09/23/2034 | Expiration date of the newly granted stock options. |
| 09/24/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.